Reported Saturday, Anito-Cel Demonstrates 96% ORR And 74% CR/sCR In iMMagine-1 Relapsed/Refractory Multiple Myeloma, Supporting Planned 2026 Commercial Launch

Benzinga · 1d ago
  • Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time --
  • Overall MRD negativity was 95% and sustained MRD negativity for >6 months was 83%, both at 10-5 sensitivity level --
  • 12-month PFS and OS rates were 82.1% and 94.0%; 18-month PFS and OS rates were 67.4% and 88.0%; 24-month PFS and OS rates were 61.7% and 83.0% --
  • To date, no delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barré syndrome, and no immune effector cell-associated enterocolitis have been observed with anito-cel to date; all patients were dosed at least 12 months ago --
  • The company reiterates its planned 2026 commercial launch --
  • iMMagine-1 data to be presented during an oral presentation at the ASH Annual Meeting on Saturday, December 6, 2025 --
  • Company to host a live webcast event with an expert panel of clinicians during ASH --